Search | Clinical Trials Finder

Conditions: Healthy
Interventions: LY2801653; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Healthy Subjects
Interventions: Bosutinib; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Tuberculosis
Interventions: SQ109; Drug
Lead sponsor: Sequella, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy Volunteers
Interventions: Venetoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Renal Impairment, Tuberculosis
Interventions: PA-824; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 3
States / cities: Miami, Florida • St Louis, Missouri • Knoxville, Tennessee

Conditions: Metabolic Syndrome
Interventions: High Protein Diet, Exercise; Behavioral
Lead sponsor: University of Georgia; Other
Eligibility: 50 Years to 64 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Athens, Georgia

Conditions: Healthy
Interventions: TP 3654; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Formulation Bridging, Food Effect
Interventions: PBI-200 Tablet, PBI-200 Capsule, PBI-200 Suspension; Drug
Lead sponsor: Pyramid Biosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Surgical Site Infection
Interventions: high-fiber/low fat, fermented; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Stanford, California

Conditions: Healthy
Interventions: IPI-145 (duvelisib), IPI-145; Drug
Lead sponsor: SecuraBio; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy Volunteers
Interventions: DZD9008, Placebo; Drug
Lead sponsor: Dizal Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy
Interventions: Molnupiravir; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Inflammatory Bowel Disease
Interventions: TD-1473, Itraconazole; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Diabetes
Interventions: High Saturated Fat Diet; Other
Lead sponsor: Kevin Davy; Other
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Blacksburg, Virginia

Conditions: Nutritional Status
Interventions: GSK1325756; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Obesity, Visceral, Cardiovascular Diseases, Fat Disorder
Interventions: Liraglutide, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 35 Years and older
Enrollment: 235 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy Volunteers in Fed and Fasted State
Interventions: Dexmethylphenidate; Drug
Lead sponsor: Cingulate Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Opioid-Related Disorders, Pain, Acute, Pain, Postoperative
Interventions: Norco 5Mg-325Mg Tablet, GRT7014 - Abuse Deterrent Tablet; Drug
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Insulin Sensitivity, Obesity
Interventions: Cold exposure, Cold exposure plus propranolol, Thermoneutral Conditions, Cold water consumption, Tepid water consumption, Exercise, Meal consumption; Other
Lead sponsor: Rutgers University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Advanced Solid Tumor, Advanced Lymphoma
Interventions: AN4005-dose level 0, AN4005-dose level 1, AN4005-dose level 2, AN4005-dose level 3, AN4005-dose level 4, AN4005-food effect; Drug
Lead sponsor: Adlai Nortye Biopharma Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 4
States / cities: Hackensack, New Jersey • The Bronx, New York • Greenville, South Carolina + 1 more

Conditions: Hypertension
Interventions: Levamlodipine, Amlodipine, Amlodipine, Levamlodipine; Drug
Lead sponsor: Conjupro Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Healthy
Interventions: high fat meal; Other
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Greenhouse Gas Emissions, Water Use, Land Use
Interventions: VEG2, OMNI2; Behavioral
Lead sponsor: Game Changers Institute; Other
Eligibility: 18 Years to 40 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Laguna Niguel, California

Conditions: Pneumonia
Interventions: Ketogenic feeding, Standard feeding; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 55 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Birmingham, Alabama

Search by objective public record fields.

A Study of LY2801653 in Healthy Participants Who Are Not Able to Have Children

Study to Determine the Effect of a High-Fat Meal on the Relative Bioavailability and Pharmacokinetics of a Single Dose of Bosutinib Administered Orally to Healthy Subjects

Escalating Single-dose Safety, Tolerability, and Pharmacokinetics of SQ109 in Healthy Volunteers

A Study to Assess Food Effect of Venetoclax New Tablet Formulation in Healthy Female Participants

Single-Dose Study to Evaluate the PKs of Pretomanid in Participants With Renal Impairment Compared to Participants With Normal Renal Function

Exercise-Induced Epigenetic Modifications in Obese Aging Women

Assessment of Relative Bioavailability and Effect of Food on Capsule and Tablet Formulations of TP-3654

A Formulation Bridging and Food Effect Study of PBI-200 in Healthy Volunteers

Effect of Preoperative Diet on Perioperative Gut Microbiome

Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145

Assessing the Safety, Tolerability and Pharmacokinetics(PK) of DZD9008 and the Effect of Low-fat Meal on PK of DZD9008 in Healthy Adult Participants

A Study to Evaluate Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants (MK-4482-011)

Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study

Effect of High Fat Diet on Muscle Metabolism

Pharmacokinetics and Safety of GSK1325756 in Elderly Subjects and Adult Subjects of in the Fed and Fasted States and in the Presence of a Proton Pump Inhibitors

Impact of Liraglutide 3.0 on Body Fat Distribution

In-clinic Crossover Study in Subjects With Two Treatments (Fed vs Fasted)

A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults

The Effect of Brown Adipose Tissue Activation on Insulin Sensitivity in Humans

First in Human, Dose Escalation Study of AN4005

Bioavailability of 5 mg of Levamlodipine Maleate Tablets Versus 10 mg of Amlodipine Besylate Tablet in Healthy Subjects

Impact of a High-fat Meal on Assessment of Clopidogrel-induced Platelet Inhibition in Healthy Subjects

The Environmental Costs of Building Human Muscle

Ketogenic Approach to Restore Muscle in Older Patients With Community-Acquired Pneumonia - KARMA-P Trial